28 results
Thumbnail

D1.342 - Therapeutic Potential of LCAA-PSF in Atopic Dermatitis: Insights from an MC903-Induced Mouse Model

Thumbnail

D1.349 - Age-related fungal molecular clusters revealed by allergen chip assay in Eastern France

Thumbnail

D1.352 - Assessment of the Efficacy of Mepolizumab in Modulating Disease Activity in Eosinophilic Granulomatosis with Polyangiitis: A 12-Month Analysis Evaluating the Birmingham Vasculitis Activity Score

Thumbnail

D1.343 - Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis

Thumbnail

D1.344 - Role of nodular lymphoid hyperplasia as immunologic precursor of IBD development in patients with IBS-like symptoms: an observational, ambispectic, muliticenter study “The NILO study”

Thumbnail

D1.345 - Biologic Agents in Neurosarcoidosis: Efficacy and Future Perspectives from a Single-Center Cohort Study

Thumbnail

D1.346 - Immunology and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers in stratifying disease risk and severity for precision medicine

Thumbnail

D1.347 - Biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms

Thumbnail

D1.350 - A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes

Thumbnail

D1.351 - The impact of Lactobacillus on the expression of NLRP3, IL-1β and HMGB1 in women with endometriosis associated infertility

Thumbnail

D1.353 - When eosinophils surpass the limits without a known cause

Thumbnail

D1.355 - Impact of mesothelin in women with endometriosis

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"